• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Certara introduces pharmacokinetic (PK) data solution

Certara introduces pharmacokinetic (PK) data solution

April 19, 2017
CenterWatch Staff

Certara, a provider of decision support technology and consulting services for optimizing drug development and improving health outcomes, announced the launch of a new solution for preparing, analyzing and submitting PK data in Clinical Data Exchange Standards Consortium (CDISC) format. CDISC supports the acquisition, exchange, submission and archiving of nonclinical and clinical data.

David Munro, president of Certara’s software division, said, “We have developed these new tools and services to remove the time-consuming task of converting data to CDISC format manually. Manual efforts are both time-consuming and more error prone, which can slow the drug approval process.”

The FDA now requires that clinical and nonclinical study data for all new drug applications (NDAs), abbreviated NDAs (ANDAs) and biologics license applications (BLAs) be submitted electronically in CDISC format. On Dec. 17, 2017 that requirement will extend to all investigational new drug applications (INDs). 

In 2016, there were 160 NDAs and BLAs, 864 ANDAs and 786 INDs submitted to FDA.

Aside from FDA, Japan’s Pharmaceuticals and Medical Devices Agency has also adopted the CDISC standard for clinical data. In addition, the European Medicines Agency, Korea Ministry of Food and Drug Safety, and the China Food and Drug Administration are considering using CDISC standards.

Certara’s CDISC PK solution includes software, services and consulting:

  • Phoenix CDISC Navigator provides a user-friendly interface that seamlessly imports CDISC data into Phoenix, converts CDISC data into an analysis-ready format, and then exports CDISC formatted PK parameters. It is ideal for current users who perform PK non-compartmental analysis (NCA) in Phoenix WinNonlin.
  • Phoenix CDISC Workflow Templates are available for Phoenix users who require automated preparation of NCA Standard Data Tabulation Model (SDTM) clinical and Standard Exchange of Non-Clinical Data (SEND) nonclinical data sets in CDISC-ready formats.
  • Certara Strategic Consulting is the largest provider of expert PK and PK/pharmacodynamic modeling services and can provide datasets in CDISC-compliant format.

Upcoming Events

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 11Feb

    Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • TechInnovation-360x240.png

    Pace of Technology Innovation in Trials Could Slow After Pandemic Eases

  • AskTheExperts-360x240.png

    Ask the Experts: Certifying and Maintaining Copies of Original Source Documents

  • Resources-360x240.png

    Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources

  • FocusinRed-360x240.png

    Return to Focus on Risk Management Postpandemic Could Prove Challenging to Sites

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing